Clinical Trial Update: Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update evaluating MSC11FCD therapy for recurrent glioblastoma and related brain neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma
• Neoplasms Brain

Drugs mentioned

• MSC11FCD Therapy

Snippet

Sponsor: CHA University | Conditions: Glioblastoma, Adult Gliosarcoma | Phase 1, Phase 2 | Status: COMPLETED